

## IPO Expected Timetable#

Stock Code	Stock Name	Application lists close	Allotment Date	Listing Date
06606	NH HEALTH-B	2021/02/10	2021/02/17	2021/02/18

#IPO listed above are those with fundraising amount more than HK\$500M. For more IPO information, please visit [www.cfs.com.hk](http://www.cfs.com.hk) or contact our account executives or customer service officers

## Subscription Details via CASH Securities

Offer Period	2021/02/05-2021/02/10
Closing Time for Margin Application	2021/02/09 2:00pm
Subscription Fee	HKD 100
Indicative Interest Rate	0-3.38%
Days For Margin Financing	7 days

\*The deadline for margin subscription share will be changed at any time, which is available on a first-come-first-served basis.

\*\* Eligible new and existing customers who successfully activate the electronic direct debit authorization (DDA) transfer service before the termination of the IPO subscription can enjoy a 0.25% loan interest reduction.

## New Horizon Health Limited (6606.HK)

### Share Offer Highlights

Total Number of Offer Shares:	76,598,000 Shares (subject to the Overallotment Option)
- Number of Public Offer Shares:	7,660,000 Shares (subject to adjustment)
- Number of Placing Shares:	68,938,000 Shares (subject to adjustment and the Over-allotment Option)
Number of Shares per Lot:	500 Shares
Offer Price:	HKD 22.70 – 26.66 per Share
2019 Historical P/E ratio:	-
Sponsor:	Goldman Sachs, UBS

### Company Overview

Founded in November 2015, the Company is the pioneer in China's colorectal cancer screening market with ColoClear, its proprietary, non-invasive, multi-target, FIT-DNA test, being the first and only molecular cancer screening test in China approved by NMPA, according to Frost & Sullivan. ColoClear targets a 120 million high-risk colorectal cancer population in China, and enables users to collect stool sample at home and avoid invasive procedures while delivering high testing sensitivity and specificity. In its registrational trial with 5,881 enrolled subjects, ColoClear has demonstrated clinical results of a sensitivity of 95.5% for colorectal cancer and 63.5% for advanced adenoma, an overall specificity of 87.1%, NPV of 99.6% for colorectal cancer, and PPV of 46.2% for colorectal cancer and advanced adenoma collectively. It believes that its proprietary technologies, clinical performance, regulatory and operational expertise, and solid relationships with KOLs serve as high entry barriers and differentiate it from its peers.

For the year ended December 31, 2018 and 2019 and the nine months ended September 30, 2020, the Company's net losses were RMB224.87 mn, RMB106.47 mn and RMB533.76 mn respectively.

### Source

IPO Prospectus

### Contact Us

Headquarters:	22/F, Manhattan Place, 23 Wang Tai Road, Kowloon Bay, Hong Kong	(852) 2287 8788
HK Services Centre:	6/F, May May Building, 683-685 Nathan Road, Mongkok, Kowloon	(852) 2748 0110
China Services Centre:	1004A(10/F), AVIC Center, 1018 Huafu Road, Futian District, Shenzhen	(86-755) 2216 5888
	2501, Tower A, China Overseas International Centre, 838 South Huangpi Road, Huangpu District, Shanghai	(86-21) 3227 9888
	Room 3316B, Block A, China Shine Plaza, 9 West Lin He Road, Tian He District, Guangzhou	(020) 8981 7463
	Rm 2511, TBA Tower, 11 Dongguan Avenue, City East District, Dongguan	(86-769) 2223 0026



**Declaration:**

The above information is provided and distributed by CASH Financial Services Group Limited ( "CASH" ). The document is for reference only. Neither the information nor opinion expressed shall be construed, expressly or impliedly, as an advice, offer, invitation, advertisement, inducement, recommendation or representation of any kind or form whatsoever. While the information contained herein has been obtained from sources believed to be reliable, CASH or its affiliates do not represent that it is accurate or complete and it should be relied upon. CASH hereby expressly disclaims all liabilities arising out of or incidental to the accuracy and completeness of the contents and information herein contained. The contents and information in this document is subject to change without prior notice to you. Trade in securities covered by this report may be made only in those jurisdictions where the securities are qualified for trading. This document may not in whole or in part be reproduced or furnished to any person other than the addressee without written consent from CASH and CASH shall not be liable to any such third parties for loss arising from any unauthorized distribution. Securities dealing services are provided by Celestial Securities Limited, a corporation licensed to conduct Type 1 (dealing in securities) regulated activity under the Securities and Futures Ordinance.